Myriad Genetics Inc
$ 4.78
7.90%
25 Feb - close price
- Market Cap 445,562,000 USD
- Current Price $ 4.78
- High / Low $ 4.88 / 4.42
- Stock P/E N/A
- Book Value 3.94
- EPS -4.35
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.68 %
- 52 Week High 11.44
- 52 Week Low 3.76
About
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$7.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.04 | -0.2943 | 0.05 | -0.03 | 0.03 | 0.06 | 0.05 | -0.01 | 0.04 | -0.03 | -0.08 | -0.21 |
| Estimated EPS | -0.0172 | -0.01 | -0.01 | -0.0544 | 0.0303 | 0.02 | -0.01 | -0.1 | 0.01 | -0.08 | -0.08 | -0.19 |
| Surprise | 0.0572 | -0.2843 | 0.06 | 0.0244 | -0.0003 | 0.04 | 0.06 | 0.09 | 0.03 | 0.05 | 0 | -0.02 |
| Surprise Percentage | 332.5581% | -2843% | 600% | 44.8529% | -0.9901% | 200% | 600% | 90% | 300% | 62.5% | 0% | -10.5263% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.0019 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYGN
2026-02-25 12:52:11
Myriad Genetics, Inc. (NASDAQ:MYGN) reported Q4 2025 earnings, exceeding expectations with an EPS of $0.04 against a projected $-0.02. The company highlighted strong volume growth in MyRisk oncology tests and Prolaris, along with significant progress on its cancer care continuum strategy, including the upcoming alpha launch of Precise MRD for breast cancer. Myriad Genetics also reaffirmed its full-year 2026 financial guidance, anticipating sequential revenue growth throughout the year despite some near-term headwinds in prenatal testing.
2026-02-24 23:52:11
Myriad Genetics Inc. has filed with the SEC for a mixed shelf offering of up to $200 million. This news comes amidst other developments for the company, including upcoming presentations at the 2026 Asco-Gu Conference, recent analyst target adjustments, and its latest quarterly and full-year earnings reports. Myriad Genetics is a genetic testing and precision medicine company focusing on Oncology, Women's Health, and Mental Health.
2026-02-24 16:52:55
Shares of Myriad Genetics (MYGN) rose 4.9% after the company reported better-than-expected fourth-quarter 2025 earnings, surpassing analyst forecasts for both revenue and profit. The company posted an adjusted profit of $0.04 per share against a forecasted loss, and its adjusted EBITDA more than doubled expectations. Despite flat quarterly revenue year-on-year, strong profitability and positive full-year EBITDA guidance drove investor optimism.
2026-02-24 14:52:56
Myriad Genetics, Inc. will present new data at the 2026 ASCO-GU conference highlighting the clinical impact of its Precise MRD, Prolaris, and MyRisk tests in cancer care. The data underscore the tests' roles in molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment. Multiple studies will showcase the performance of Precise MRD in genitourinary cancers, the prognostic power of Prolaris in prostate cancer, and the utility of MyRisk for germline testing in localized prostate cancer.
2026-02-24 13:52:55
Myriad Genetics announced it will present six abstracts at the ASCO-GU 2026 conference, highlighting clinical data for its Precise MRD, Prolaris, and MyRisk oncology tests. Key findings include ultra-sensitive ctDNA detection by Precise MRD, strong prognostic power of Prolaris for prostate cancer, and consistent germline variant identification by MyRisk across different prostate cancer risk groups. This data reinforces Myriad's focus on oncology diagnostics and suggests its tests offer significant insights beyond standard approaches, potentially broadening testing scope.
2026-02-24 12:52:56
Myriad Genetics, Inc. (MYGN) reported stronger-than-expected Q4 2025 earnings and revenue, leading to a significant jump in its stock price. Despite a 0.4% year-over-year revenue decline, adjusted earnings per share exceeded estimates by 350%. However, the company's gross margin decreased, and Mental Health revenues were negatively impacted by a policy change.
